原发性肝癌中多药耐药基因表达及其对介入治疗疗效的影响  

MDR1:Expression and Effect on Interventional Therapy of Hepatocellular Carcinoma

作　　者：刘瑞宝[1] 徐克[1] 张曦彤[1] 冯博[1] 赵仲春[1] 苏红英[1] 

机构地区：[1]中国医科大学附属第一医院放射科,辽宁沈阳110001

出　　处：《中国医学影像技术》2003年第5期617-619,共3页Chinese Journal of Medical Imaging Technology

摘　　要：目的　探讨原发性肝癌中多药耐药基因编码的P 糖蛋白 (Pgp)表达对介入治疗疗效的影响。方法　 47例原发性肝癌介入治疗前穿刺活检 ,采用SABC免疫组化方法检测Pgp表达。依肿瘤分期及病人状况 ,应用常规剂量及半剂量化疗药物进行栓塞治疗。结果　Pgp阳性率为 72 .3 % ( 3 4/ 47)。常规剂量组Pgp阴性患者有效率明显高于阳性患者 (P <0 .0 5 ) ,半剂量组二者无显著差异 (P >0 .0 5 ) ;Pgp阳性患者应用不同药物剂量疗效间无显著差别 (P >0 .0 5 ) ,Pgp阴性患者疗效与剂量呈正相关。结论　多药耐药是影响介入治疗疗效的重要因素 ,治疗前检测Pgp表达对制定个体化治疗方案有重要意义。Objective To investigate the expression of P-glycoprotein (Pgp) that encoded by multidrug resistance gene (MDR1) and it's effect on interventional therapy of hepatocellular carcinoma (HCC). Methods Biopsy was performed in 47 patients with HCC prior to transcatheter arterial chemoembolization (TACE) and Pgp expression was detected by SABC immunohistochemical method. Normal and half dose of anticancer agents were used in the treatment of TACE according to Okuda's staging and general condition of the patients. Results Pgp expression was observed in 34 of the 47 patients ( 72.3% ). Response rate was significant high in the patients of negative Pgp expression than that of positive ones when treated with normal doses of anticancer agents and no significance were founded when treated with half doses during TACE ( P > 0.05 ).There was no significant difference in patients of positive Pgp expression when treated with different doses of anticancer agents ( P >0.05), however in the case of negative ones the response to TACE was positive correlation to the doses of anticancer agents. Conclusion MDR1 play an important role in affect the response of interventional therapy.Detecting Pgp prior to TACE has instructive significance for interventional treatment according to individuals.

关 键 词：原发性肝癌 多药耐药 P-糖蛋白 化疗栓塞术 

分 类 号：R815[医药卫生—放射医学] R735.7[医药卫生—临床医学]